UCB (OTCMKTS:UCBJY) Stock Price Crosses Above 50-Day Moving Average – Should You Sell?

UCB SA (OTCMKTS:UCBJY)’s share price crossed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $143.16 and traded as high as $147.94. UCB shares last traded at $146.91, with a volume of 25,401 shares.

Analysts Set New Price Targets

A number of research analysts recently issued reports on UCBJY shares. Zacks Research downgraded UCB from a “hold” rating to a “strong sell” rating in a report on Thursday, June 11th. Barclays cut UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, June 15th. Finally, Jefferies Financial Group upgraded UCB to a “moderate sell” rating in a research report on Monday, June 22nd. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, UCB presently has a consensus rating of “Hold”.

UCB Price Performance

The company has a quick ratio of 1.04, a current ratio of 1.38 and a debt-to-equity ratio of 0.20. The stock’s 50 day moving average is $143.32 and its 200-day moving average is $147.86.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.